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Abstract. Food can impact the pharmacokinetics of a drug product through several mechanisms, including
but not limited to, enhancement in drug solubility, changes in GI physiology, or direct interaction with the
drug. Significant food effects complicate development of new drugs, especially when clinical plans require
control and/or monitoring of food intake in relation to dosing. The prediction of whether a drug or drug
product will show a human food effect is challenging. In vitro models which consider physical–chemical
properties can classify the potential for a compound to demonstrate a positive, negative or no food effect,
and may be appropriate for screening compounds at early stages of drug discovery. When comparing
various formulations, dissolution tests in biorelevant media can serve as a predictor of human drug
performance under fasted and fed conditions. Few in vivo models exist which predict the magnitude of
change in pharmacokinetic parameters in humans when dosing in the presence of food, with the dog
appearing to be the most studied species for this purpose. Control of gastric pH, as well as the amount and
composition of the fed state in dogs are critical parameters to improving the predictability of the dog overall
as a food effect model. No single universal model is applicable for all drugs at all stages of drug
development. One or more models may be required depending whether the goal is to assess potential for a
food effect, determine the magnitude of change in pharmacokinetic parameters in the fed/fasted state, or
whether formulation efforts have the ability to mitigate an observed food effect.
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INTRODUCTION
Food can impact the pharmacokinetics of a drug product
through several mechanisms, such as delay in gastric empty-
ing, stimulation of bile flow, changes in gastrointestinal (GI)
pH, alterations in luminal metabolism, or interactions of the
drug with the food itself (1,2). The drug absorption process
can be affected by many factors, including calorie content
(low vs high calorie meals), nutrient composition (protein,
carbohydrate-rich or high-fat meals), volume, temperature of
the meal itself, and fluid ingestion. Food also increases blood
flow to the liver (splanchnic blood flow); therefore, changes
in first pass extraction that occur as a result, may cause
differences in bioavailability between the fed and fasted state.
For compounds with saturable first pass extraction, the
bioavailability will increase with food intake; whereas the
opposite will occur if hepatic enzymes are not saturated
during first pass. Propranolol, metoprolol and propafenone
are examples of drugs with high first-pass metabolism whose
pharmacokinetics are impacted by food (3). Michael Camil-
leri of the Mayo Clinic published a thorough review on the
topic of changes in human GI physiology with food intake (4).
This reference provides significantly more detail on many of
the mechanisms discussed above.
In addition to physiologic considerations, factors such as
non-specific binding, sequestration, or chemical instability can
cause drug–food interactions. If a drug chelates with ions
present in the ingested meal, drug dissolution and/or absorp-
tion may be reduced. The meal itself may pose a physical
barrier that prevents drug diffusion to the site of absorption,
likewise resulting in decreased bioavailability. Drug instability
as a result of acid degradation may be exacerbated by
prolonged gastric residence after food ingestion.
For particularly lipophilic drugs or large molecular
weight macromolecules, lymphatic uptake can be increased
by the presence of a high-fat meal, thereby lowering plasma
drug levels (5,6). Gershkovich and Hoffman suggest that
changes in drug disposition for certain lipophilic compounds
may occur when the drug interacts with triglyceride-rich
lipoproteins (TRL), which elevate as a result of consumption
of high fat meals (7). This work proposes that various drugs
bindtoTRLatdifferentsitesin vivo. For example, if this occurs
within the enterocyte, lymphatic uptake is likely and first pass
metabolism is by-passed (8). For other lipophilic compounds, a
sequestration of drug by TRL takes place in the plasma after
the absorption process is complete, resulting in a decrease in
parameters such as volume of distribution and clearance. In
these cases, the observed food effect is better mechanistically
explained by postprandial hyperlipidemia.
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(FDA) recognized the potential for food to alter the
pharmacokinetics of drug products and established standards
for the design of clinical food effect studies. In the FDA
Guidance on Food-Effect Bioavailability and Fed Bioequiva-
lence Studies, it is recommended that drug products are
administered under fasted and fed conditions, where the fed
state consists of a high fat meal (1,000 calories; 50% from fat) to
maximize the potential for an observable food effect (9). If the
90% confidence interval (CI) for the population geometric
means between fed and fasted treatment for Cmax and AUC do
not meet the 80–125% bioequivalence (BE) criterion, a food
effect is demonstrated, and the potential for clinical signifi-
cance of the food effect should be considered.
Several challenges exist in the development of com-
pounds that exhibit food effects. If a high fat meal is required
to obtain efficacious drug levels, there is potential for sub-
therapeutic dosing in patients taking the drug without food.
For compounds with a narrow therapeutic index, changes in
bioavailability, particularly in the positive direction, may
produce unwanted side effects. As a result, the clinical plan
may require control and/or monitoring of food intake in
relation to dosing.
Competition with other drugs which do not exhibit a
food effect may even offer a commercial advantage. Auiler et
al. compared the effect of food on the exposure of an
extended release methylphenidate formulation (Concerta
®)
to that of an extended release amphetamine formulation
(Adderall XR
®). Both compounds are used for the treatment
of attention-deficit/hyperactivity disorder (ADHD). In this
study, the early plasma concentrations of amphetamine from
the Adderall XR
® formulation were lower in patients when
the drug was administered with a high fat breakfast.
However, drug exposure for methylphenidate from the
Concerta
® formulation was not affected by food. The authors
concluded less variability in drug exposure in patients taking
Concerta
® compared to Adderall XR
® particularly if meal
intake varied (10). Although these results were challenged
because the study compared partial area AUCs as opposed to
traditional BE criteria, it illustrates how food effect data can
also be used to promote market advantage between drugs in a
therapeutic class (11).
Despite the implications outlined above, the prediction
of whether a drug or drug product will show a human food
effect is challenging, and no one model is sufficiently
comprehensive to accurately predict food effect in all cases.
Depending on the particular stage of drug development, the
rationale for determining food effect may be different, thus
influencing the choice of which model is most appropriate.
The present work reviews the current methods for the
prediction of human food effect and compares the advantages
and disadvantages of various in vitro and in vivo approaches.
IN SILICO METHODS FOR PREDICTING FOOD
EFFECT
Singh compared whether aqueous solubility, dose/solu-
bility ratio and Log P could be correlated to human fed/fasted
AUC through the analysis of over 100 structurally diverse
compounds (12). Aqueous solubility and lipophilicity played
a “predominant role” in anticipating human food effect.
Consideration of the drug’s dose in relation to its solubility
(dose/solubility ratio) further improved predictability as
compared to solubility alone. This work concluded that
although food effect was able to be correlated to these
physicochemical properties, it was more difficult to make
quantitative prediction of the magnitude of AUC change
between fasted and fed treatments. Other biopharmaceutic
properties, such as permeability, were not considered.
Wu and Benet suggest food effect can be anticipated on
the basis of both solubility and permeability as described by
the Biopharmaceutics Classification System (BCS) (13,14).
Figure 1 summarizes the effect of food on the direction of
change in extent of drug exposure (AUC) as a function of
BCS class. In general, BCS Class I compounds are least
affected by food. Those belonging to BCS Class II (low
solubility, high permeability) are more likely to show a
positive food effect, due to increased in vivo solubility in the
fed state. It is generally recognized that not all BCS Class II
compounds should be grouped together. Rather, the category
can be subdivided into weak acids, weak bases, and lipophilic
compounds. Each will respond differently to food effect. For
weak acids and weak bases with high pKas (a majority of
compounds in this class), meals which stimulate bile flow and
enzymatic activity enhance dissolution and subsequently
result in positive food effects. However, it is possible for a
compound with a low pKa to actually precipitate in the
stomach or upper small intestine if the pH of the GI contents
is elevated due to meal ingestion. In those instances,
bioavailability could actually decrease for a BCS Class II
compound. BCS Class III (high solubility, low permeability)
drugs tend to have negative food effects, particularly if food
interacts with drug absorption. For BCS Class IV compounds,
it is more difficult to anticipate the direction of the change in
AUC. This could be because some BCS Class IV compounds
have been “misclassified” based on strict definition of the in
vitro criterion of the BCS. When these types of compounds
are dosed, their ability to perform in vivo like BCS Class II or
III compounds will influence how food may impact AUC. If
the poor in vitro solubility of a BCS Class IV compound is
improved in vivo (possibly through formulation efforts) it
may behave like a BCS Class III compound. Other Class IV
compounds may have in vitro intestinal permeability just
below a suitable high permeable reference compound in vitro,
yet in vivo may be well absorbed throughout the entire GI
tract, or be a substrate for an uptake transporter. Those
would behave like a BCS Class II compound, and show
increases in AUC in the presence of food. More challenging
are those Class IV compounds with both altered in vivo
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Fig. 1. The effect of food on the direction of change in extent of drug
exposure (AUC) as a function of BCS class
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which make it difficult to anticipate the direction of food
effect.
Gu et al. compared BCS Class to the observed human
food effect of 92 sets of clinical data (15). This analysis
revealed that 67% of BCS Class I compounds in the data set
showed no food effect, 71% of the BCS Class II compounds
had a positive food effect, and 61% of BCS Class III
compounds showed a negative food effect. Of the Class IV
compounds in this dataset, a large majority (73%) showed a
positive food effect. To improve predictability, the authors
generated a statistical model which incorporated maximum
absorbable dose (MAD), dose number and LogD. For the 92
compounds in this dataset, the probability of correctly
predicting the category of food effect (positive, negative, or
no food effect) was 80%. However, there was a substantial
difference in accuracy of prediction depending upon the
direction of the food effect. The correct predictions were 97%
for positive food effects, 79% for negative food effects and
68% for no food effects.
These methods classify compounds as likely to show a
positive, negative, or no food effect. The advantage to these
approaches is that parameters such as solubility and perme-
ability are relatively easy to determine with minimal amount
of drug substance. Therefore, at early stages of drug
discovery, it is possible to screen many compounds for food
effect “potential”. Unfortunately, these particular methods
are less accurate at predicting the magnitude in the change in
pharmacokinetic parameters (such as Cmax or AUC) in the
presence of food. It is also not possible to compare several
different formulations, and provides no mechanistic under-
standing as to the cause of the food effect.
More recent work in the modelling and simulations area
has demonstrated the possibility of predicting a compound’s
pharmacokinetic profile in the fed and fasted state, using
commercially available software packages. Jones et al. simu-
lated the impact of food on the pharmacokinetics of several
Roche compounds (16). These authors developed physiolog-
ically based pharmacokinetic models (PBPK) in GastroPlus
®
using permeability, solubility, metabolism and distribution
data for each compound. Incorporation of physiological
parameters, in combination with drug solubility data in
various biorelevant medias, allowed for the oral pharmacoki-
netics of each drug to be simulated under fasted and fed
conditions. For the six dissolution rate limited compounds
studied in this work, the simulations were able to capture the
magnitude of the observed human food effect. Although a
detailed discussion of PBPK modelling is beyond the scope of
this work, it is a powerful tool for predicting human
pharmacokinetic profiles throughout the various stages of
drug discovery and development (17).
BIORELEVANT DISSOLUTION
Several groups have reported on the use of dissolution in
biorelevant media as a predictor of drug performance in
humans under fasted and fed conditions. Specialty dissolution
medias have included milk, fasted simulated small intestinal
fluid (FaSSIF), fed simulated small intestinal fluid (FeSSIF),
and/or modifications to these medias in phospholipid or bile
salt content, pH, or inclusion of lipolytic enzymes (18–20).
Food effects on drug absorption are generally better
predicted when using biorelevant media containing bile salts
and lecithin as compared to the traditional USP compendial
media such as simulated gastric fluid (SGF) and simulated
intestinal fluids (SIF). It is, however, difficult to design a
universal simulated fed state media for use with all com-
pounds because the composition of in vivo fed state fluids is
highly dependent on the ingested meal itself. The concentra-
tion of bile salt and lecithin in standard FeSSIF is based on
average peak bile output and therefore, may not be
appropriate in cases where drugs are dosed at various times
after meal ingestion as compared to when they are co-
administered with food. Nicolaides et al. recommends starting
with milk and adding components such as pepsin or lipase to
improve correlations when working with specific compounds
(18).
Dissolution data for several BCS Class II compounds
(danazol, ketoconazole, atovaquone, and troglitazone) was
shown to correlate well to observed human fed and fasted
pharmacokinetic data (20). For danazol, dissolution profiles
in standard SIF were incomplete, but use of simulated fasted
and fed intestinal media was able to suggest a food effect was
anticipated. This work also showed the importance of volume
adjustment in dissolution tests such that more physiologic
volumes were considered.
Biorelevant dissolution tests offer several advantages.
They are considered more physiologically appropriate than
standard compendial USP dissolution medias, and examples
exist where their use can allow for the anticipation of
bioavailability improvement in the fed state. In some cases,
this technique has been shown to predict fed state pharma-
cokinetic profiles for lipophilic drugs in humans. Biorelevant
dissolution tests can be utilized to compare several prototype
formulations in vitro, to select a best one prior to the
investment of human clinical testing. One disadvantage is
that dissolution tests require a formal formulation, thus this
technique may not be as helpful to early preclinical drug
development. Additionally, composition of the media may
require optimization to improve predictability; therefore a
“one size fits all” approach is unlikely to work for all
compounds. For this optimization to occur, actual human
data must be available, which implies a compound has
already progressed into clinical development.
IN VIVO METHODS
Although certain physiological differences in gastric pH,
gastric emptying and intestinal transit time exist between dogs
and humans, the dog is the most studied species for
understanding or predicting human food effect (21–25).
Fewer reports of food effect studies have been conducted in
species such as rat, monkey, or mini-pig. The size of the rat
limits the ability to dose traditional dosage forms, such as
capsules and tablets, although when a drug can be adminis-
tered as a liquid, the rat can be used. In addition, rats do not
possess a gallbladder, thus secretion of bile to the duodenum
is a continuous process. This differs to humans, where bile
secretion is stimulated by the presence of food. The overall
volume of rat GI fluid is also low in relation to other species.
Monkeys may be a commonly used species for pharmaceuti-
cal testing; yet, there are few papers which report the utility
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285 Current Methods for Predicting Human Food Effectof this species for food effect studies. Kondo et al. showed the
gastric pH after feeding of a standard biscuit-type meal to be
higher in cynomolgus monkeys than the fed state pH in
humans (26). Thus, optimization of the fed state test meal
may be required before the monkey could yield food effect
data similar to the human. In a recent paper by Grove et al.,
the mini-pig was used to investigate the effect of food on
several lipid-based formulations of seocalcitol, a poorly
soluble compound (27). Although the biliary system and
pancreatic duct in minipigs and humans are more physiolog-
ically comparable (24,28), the overall use of this species as a
food effect model is limited throughout the literature. The
advantage of the dog is that it is a more appropriate model
for dosing solid oral dosage forms. When interested in
considering formulation effects, as well as the impact of the
drug itself, dogs are a better preclinical species for this work.
In the dog, the amount and composition of the fed state
test meal varies substantially. Table I summarizes the type of
test meal, amount, and outcome or purpose of several food
effect studies performed the dog. Some studies were initiated
because a food effect was observed clinically in humans, and
the dog studies were designed retrospectively to determine if
the food effect would have been predicted (5,29,30). Others
used the dog under varying fed state conditions to optimize
formulation strategies (31–34).
Wu et al. performed a series of experiments using the dog
to evaluate prototype formulations of MK-0869, an NK1
antagonist (33). This compound entered early clinical devel-
opment, where a food effect was observed in human subjects
receiving a traditional tablet formulation of this BCS Class II
compound. New formulations intended to increase in vivo
dissolution through particle size reduction were designed and
administered to beagle dogs, where the fed state consisted of
374 g of Alpo dog food. The dog was used to both optimize
the formulation in terms of particle size reduction, as well as
to guide the method at which nanoparticles were incorporat-
ed into a more traditional solid dosage form. For this
compound, the data obtained in the dog was in very good
agreement with human data.
Dogs were also found to be well suited for studying the
absorption and food effect of different theophylline formula-
tions (34). Despite known GI differences between the dog
and human, the dog accurately predicted the rate and extent
of theophylline absorption from several theophylline formu-
lations in humans. When dogs were administered an entire
human high fat meal, the results were in good agreement with
those observed in human subjects for each formulation
studied.
In an effort to design a predictive food effect model, a
variety of BCS Class I–IV compounds were evaluated in
pentagastrin pretreated dogs, administered a 50 g aliquot of
FDA high fat meal (35). This model predicts changes in
human Cmax and AUC in the presence of food, which are
reflective of the magnitude of change in these parameters
observed in humans. Table II illustrates that the fed/fasted
Cmax and AUC in the dog using this set of optimized
experimental conditions were in fairly close qualitative
agreement with those observed in humans. The amount of
test meal (50 vs 100 g), as well as control of gastric pH with
pentagastrin, were important parameters to aligning fed/
fasted Cmax and AUC ratios to those observed in humans
across a series of diverse compounds. This model can
accommodate various formulation types (from suspension in
capsule to formulated product), and is particularly useful at
the preclinical drug development phase for determining
whether a new drug substance may be subject to a food effect.
Although it is easy to administer various formulations
and test meals to the dog, this species is not always
appropriate for predicting changes in human pharmacokinet-
ics in the presence of food. Fotaki et al. showed the mongrel
dog to overestimate absorption of the poorly permeable
compound, L-sulpiride (36). In this work, Cmax, AUC and %F
were higher in the dog than those obtained in humans. Loose
epithelial junctions in dogs and/or inhibition of intestinal P-
glycoprotein by high bile salt levels in fed dogs may explain
the disconnect to observed human data, especially for this
drug with poor intestinal permeability. In this example, in
vitro dissolution data was more useful to predicting human
food effect.
It is possible for the dog to over-predict human food
effect. Paulson et al. administered celecoxib to dogs receiving
low-, medium-, and high-fat high fat human meal homoge-
nates and showed the food effect to be much greater than that
observed in humans (30). In this study, the total volume of
test meal administered to the dogs was similar to a full human
meal and may partly contribute to the over-prediction.
Despite many encouraging pieces of data, dogs are not
absolute surrogates for humans in many ways. Martinez et al.
have published extensively on known physiologic differences
which aid in bridging the gap to explaining interspecies
differences in bioavailability (6). In addition to the consider-
ation of differences in presystemic drug metabolism between
dog and human, other factors such as diet, formulation,
physical–chemical properties of the drug, fluid pH, and GI
physiology are important in explaining species-related differ-
Table II. Comparison of Fed/Fasted Pharmacokinetic Parameters in
the Dog vs Human for Compounds with Various Propensities for
Food Effect (35)
Compound Parameter Canine fed/fast Human fed/fast
Atazanavir AUC 2.7 1.7
Cmax 2.0 1.6
Celebrex AUC 2.3 1.2
Cmax 3.0 1.3
HIV attachment
inhibitor
AUC 2.2 2.5
Cmax 1.7 2.5
Ravuconazole AUC 5.5 4.0
Cmax 5.1 4.0
Pravastatin AUC 0.66 0.69
Cmax 0.67 0.51
Metformin AUC 0.85 0.75
Cmax 0.55 0.60
Aripiprazole AUC 1.7 1.2
Cmax 1.0 1.1
Irbesartan AUC 0.83 1.0
Cmax 0.69 1.0
Factor Xa inhibitor AUC 1.4 1.0
Cmax 1.3 1.1
All dogs pentagastrin pretreated (6 μg/kg) prior to fasted and fed
studies. A 50 g aliquot of FDA meal was administered prior to dosing
for fed studies.
286 Lentzences in bioavailability. Failure of the dog to quantitatively
predict human food effect may be attributable to these
factors. However, it generally appears throughout the litera-
ture that control of dog gastric pH and the amount and/or
composition of the fed state are important parameters to
improving the predictability of the dog overall as a human
food effect model.
SOLUBILITY IN INTESTINAL ASPIRATES
Determination of drug solubility in human and canine
intestinal contents, obtained in both the fed and fasted state,
has recently been reported. This technique should provide a
more accurate measure of in vivo drug solubility. Kostewicz et
al. showed solubility of danazol, felodipine, and griseofulvin
to be greater in dog aspirates than human, mainly due to the
higher levels of bile salts present in dog fed state intestinal
contents as compared to human (37). This is in contrast to
work by Persson et al. which showed some of these same
compounds to have similar drug solubility in canine fed
intestinal fluid to that determined in fed human intestinal
fluid (38). It is noteworthy that the administration of the meal
and the methods for obtaining the biological fluids in the dogs
and humans differed in the latter study. Here, the test meal
used in dog and human consisted of NuTRIflex
®, a liquid
nutritional drink containing partially metabolized triglycer-
ides and protein. This supplement contains only about 25% of
the fat of the standard FDA breakfast.
In another study, Kalantzi et al. administered 500 mL of
Ensure
® in the dog, prior to collecting dog intestinal
aspirates, and determined the solubility of dipyridamole and
ketoconazole (39). The results were compared to solubility in
human intestinal aspirates obtained under similar meal and
collection conditions. These authors showed the bile salt
content in dog aspirates to be higher than those obtained in
humans, and concluded this difference as the likely cause for
the poor agreement in drug solubility between dog and
human intestinal fluids.
As was the case with in vivo pharmacokinetic studies in
the dog, meal composition and volume appear to influence
composition of fed state intestinal fluids in dog, particularly in
regard to the amount and nature of the bile salt content of the
aspirates. Based on the Persson study, the meal volume and
caloric content used in the dog were smaller, and drug
solubilities in these aspirates were more closely reflective of
human intestinal drug solubility. This suggests that choice of
meal administered in the dog may need to be optimized to
further improve its correlation to human fed intestinal fluids.
The choice of test meal in the dog may strongly influence the
composition of canine fed intestinal fluid; therefore, it may or
may not be a true reflection of human fed state intestinal
medias in all cases.
CONCLUSIONS
In vitro models which consider drug solubility and
intestinal permeability are useful for determining if a
compound is likely to show a propensity for a food effect in
humans. Unfortunately, these models are unable to predict
the magnitude of change in fed/fasted parameters such as
Cmax and AUC. Dissolution in biorelevant media has been
shown to predict fed state pharmacokinetic profiles for
several lipophilic compounds and can allow for the compar-
ison of various formulations prior to in vivo clinical testing.
However, volume adjustments or modifications to the com-
position of the media may need to be optimized for specific
compounds. This may require prior knowledge of human
clinical data. In vitro dissolution and solubility studies are
only useful for food effect prediction if compounds have
dissolution or solubility limited absorption, and at best may
only be expected to correlate with changes in Cmax or AUC,
not both. Although dogs are the most studied species for
predicting human food effect, the composition, amount of the
test meal, and control of gastric pH are critical parameters to
improving the correlation of data in the dog to those ob-
served in humans. No one universal model is applicable for all
drugs at all stages of drug development. One or more models
described herein may be required depending whether the
goal is to determine potential for a food effect, predict
the magnitude of change to pharmacokinetic parameters in
the fed/fasted state, or determine whether formulation efforts
have the ability to mitigate food effect.
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